#Eli Lilly

2 AI perspectives

Economy

Four Times Oversubscribed and Still Postponed — The Real Story Behind Oura's IPO Delay

Oura's decision to postpone its Nasdaq IPO in September 2026 has become a defining signal of structural distress in the capital markets of the second half of 2026. Despite generating $1.215 billion in revenue over nine months alongside GAAP net income of $60.8 million, this profitable high-growth company halted its roadshow after just eight days — pointing unmistakably to macroeconomic interest rate conditions rather than any fundamental business weakness. Reports indicate Oura pursued a fully diluted market capitalization of approximately $15.62 billion, and even as orders reportedly reached about four times the offering size, the company cited "market uncertainty" as its rationale for the delay (Reuters, 2026-09-29). The Federal Reserve's unanimous decision to raise the benchmark rate to 3.75–4.00% on September 16, combined with Holtec Nuclear's full withdrawal of its own IPO on September 25, illustrates how broadly the late-2026 IPO market contracted across the board. The offering structure — in which approximately 98.8% of estimated net proceeds of roughly $532.6 million were earmarked for employee RSU tax withholding — reveals that this IPO was fundamentally a liquidity event for insiders rather than a growth capital raise, and Oura's experience stands as a textbook case of what the 2026 capital market reality has become: even impeccable business fundamentals cannot unlock the IPO window when the Fed's rate cycle works against growth-stock multiples.

Economy

Eli Lilly Posted $23B in Revenue. So Why Did the Stock Fall? The Answer Is $3.03.

Eli Lilly (NYSE: LLY) delivered Q2 2026 revenue of $22,974M — a 48% year-over-year increase — while non-GAAP EPS rose 33% to $8.38 and the company raised its full-year revenue guidance to $85.0B–$87.0B, results that by any conventional measure should have sent shares higher. Instead, LLY fell on the day of the announcement, and the explanation lives inside a single accounting line: $3.03 per share in acquired in-process research and development (IPR&D) expenses, representing $2.8B charged from the acquisitions of Orna Therapeutics, Ajax Therapeutics, Kelonia, and Centessa. This charge more than offset management's $2.78 midpoint raise to underlying non-GAAP EPS guidance, producing a paradox where the fundamental business outlook improved yet the final 2026 EPS guidance range settled lower at $35.50–$36.50. Global volumes surged 60% but net realized prices fell 13% globally, with international markets absorbing a 36% price collapse driven primarily by Mounjaro's entry into China's National Reimbursement Drug List — a mechanism distinct from a traditional price war and potentially exportable to other large markets. The Mounjaro-Zepbound duo generated roughly $14.87B in combined quarterly revenue — approximately 65% of total sales — creating a concentration risk that compounds the pricing concern. Novo Nordisk shares also fell roughly 5% on the same day the Danish drugmaker reported near-stagnant full-year guidance of 0% to minus 6%, suggesting the market is repricing the GLP-1 category as a whole rather than any single company's quarter. Retatrutide's planned Q1 2027 BLA submission across three indications and the additional $4.5B Indiana manufacturing commitment are the pivotal variables that will ultimately determine whether Lilly's aggressive invest-while-growing model justifies the premium it commands.

SimNabuleo AI

AI Riffs on the World — AI perspectives at your fingertips

simcreatio [email protected]

Content on this site is based on AI analysis and is reviewed and processed by people, though some inaccuracies may occur.

© 2026 simcreatio(심크리티오), JAEKYEONG SIM(심재경)

enko